Table S4.
Association of immunohistochemical staining for AGR3 with other tumor variables in a cohort of ER-negative breast cancer patients
| Variable | N (%)a
|
Statistical significanceb | |||
|---|---|---|---|---|---|
| Patients | AGR3 negative/border | AGR3 weak/moderate | AGR3 strong | ||
| Histological grade | |||||
| G1 | 1 | 1 (100.0) | 0 (0.0) | 0 (0.0) | 0.917 |
| G2 | 10 | 6 (60.0) | 3 (30.0) | 1 (10.0) | |
| G3 | 71 | 47 (66.2) | 15 (21.1) | 9 (12.7) | |
| Tumor size | |||||
| pT1 | 32 | 24 (75.0) | 5 (15.6) | 3 (9.4) | 0.729 |
| pT2 | 44 | 26 (59.1) | 11 (25.0) | 7 (15.9) | |
| pT3 + pT4 | 11 | 8 (72.8) | 2 (18.2) | 1 (9.0) | |
| Nodal status | |||||
| Negative | 34 | 25 (73.5) | 7 (20.6) | 2 (5.9) | 0.282 |
| Positive | 53 | 31 (58.5) | 13 (24.5) | 9 (17.0) | |
| Her2/neu status | |||||
| Negative | 40 | 34 (85.0) | 5 (12.5) | 1 (2.5) | 0.001 |
| Positive | 49 | 24 (49.0) | 15 (30.6) | 10 (20.4) | |
| Ki-67 | |||||
| <15% | 6 | 4 (66.7) | 2 (33.3) | 0 (0.0) | 0.626 |
| ≥15% | 42 | 30 (71.4) | 7 (16.7) | 5 (11.9) | |
Notes:
a
Number (percentage) of patients with tumors characterized by negative/border, weak/moderate, or strong expression of AGR3. Probability,
b
P, was calculated using Fisher’s exact test with the Freeman–Halton extension.
Abbreviations: AGR3, anterior gradient protein 3; ER, estrogen receptor; Her2/neu, human epidermal growth factor receptor 2.